What type of study is this?

December 8, 2025Blood

TCF3::hlf-positive b-ALL: Largest cohort study to date reveals unique molecular landscape and treatment challenges

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis reveals chemoresistance in TCF3::HLF-positive B-ALL, indicating the critical need for innovative treatment strategies.

B-ALL subtype exhibits high chemoresistance, posing severe treatment challenges.
Complex abnormalities and RAS pathway mutations identified in the majority of cases emphasize unique molecular features.
Immunophenotyping and transcriptome analysis indicate significant dysregulation of immune-related pathways.
Targeted therapies like blinatumomab and venetoclax show limited effectiveness, highlighting the need for tailored approaches.

Wang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Observational analysis reveals chemoresistance in TCF3::HLF-positive B-ALL, indicating the critical need for innovative treatment strategies.